Promethera Biosciences has added to its Series C to support its expansion into major liver diseases including nonalcoholic steatohepatitis.
Small cap British biotech Adaptimmune will combine its experimental NY-ESO SPEAR T-cell therapy with Merck’s blockbuster checkpoint inhibitor Keytruda (…
Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Learn how this…
The FDA has placed a partial clinical hold on a Phase III PD-L1 candidate from AstraZeneca due to bleeding adverse events in two clinical trials.
Investors plowed $116 million in a Series B round into Unity Biotechnology, which is focusing its early work on halting atherosclerotic disease.
The IPO raised the offer price and the number of shares sold with backing from new investors Pfizer and BB Biotech.
Allergan is buying Motus Therapeutics, a subsidiary of Rhythm Holding designed to hold its diabetic gastroparesis treatment relamorelin, under an option deal…
ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.
DBV posts peanut allergy data, TiGenix looks to file for an IPO, Oasmia is buying a cancer drug and more.
In our EuroBiotech roundup this week, NeuroVive closes its Lyon subsidiary, ObsEva misses a primary endpoint, Active Biotech offloads a cancer drug, and more.
TiGenix has dusted off its plan to file for an IPO on Nasdaq and brought in a new set of underwriters.